Navigation Links
Oncobiologics, Inc. and Fox Chase Cancer Center Announce Co-Development of a Novel Cancer Therapy Platform
Date:8/22/2011

CRANBURY, N.J. and PHILADELPHIA, Aug. 22, 2011 /PRNewswire/ -- Oncobiologics, Inc. and Fox Chase Cancer Center announced today an agreement to co-develop a novel, next-generation bi-specific antibody cancer platform with enhanced therapeutic capabilities against solid tumors. The jointly engineered platform is designed to handle multiple targets, representing a pipeline of promising cancer treatments. This research program is now underway, with preclinical studies expected in Q1-2012 for the first molecule using this platform. Financial terms were not disclosed.

The platform integrates intellectual property originated by both Oncobiologics and Fox Chase. Oncobiologics will play a key role in the discovery program that will be carried out at Fox Chase, and will engage its proof-of-concept engine to develop therapeutic products and move them through clinical trials. The two organizations expect to partner with established pharmaceutical/biopharmaceutical companies for commercialization of drug candidates resulting from the platform, and are actively seeking co-development partners.

"Fox Chase is excited about taking this important step in jointly developing a unique bi-specific antibody platform with Oncobiologics," says Kurt A. Schwinghammer, Ph.D., Vice President of Research and Development Alliances at Fox Chase Cancer Center. "We have been extremely hopeful about the promise of this therapeutic approach."  

Matt Robinson, Ph.D., the principal investigator at Fox Chase and John Cini, Ph.D., Vice President at Oncobiologics, commented, "We believe this platform can improve cancer therapies by improving tumor delivery, enhancing pharmacokinetics, and providing the opportunity for synergistic bi-specific antibody delivery."

"This is an important milestone in demonstrating our mission to increase the flow of biologic drug candidates to the patients who need them," said Pankaj Mohan, Ph.D., Founder & CEO of Oncobiologics. "Strategic partnerships with Fox Chase and other centers of excellence in cancer research are a critical element of our strategy to deliver a holistic approach for treating cancer."  

About Oncobiologics, Inc.

Oncobiologics is a discovery and proof-of-concept engine with the mission of increasing the flow of biologic drug candidates through the industry's development pipeline by eliminating technical and financial barriers. The Oncobiologics team is comprised of senior scientists and technicians from top-tier pharma and biotech organizations with extensive experience developing and commercializing successful biologic drugs. Oncobiologics operates in a state-of-the-art, 25,000-sq.-ft. multi-host facility in central New Jersey. More information can be found at http://www.oncobiologics.com.

About Fox Chase Cancer Center

Fox Chase Cancer Center is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation's first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center's nursing program has received the Magnet status for excellence three consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX-CHASE or 1-888-369-2427.

Contact:

Jeremy Caudill

Oncobiologics, Inc.
609-619-3990 ext. 216
jeremycaudill@oncobiologics.com

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE Oncobiologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Henry Schein Announces $200 Million Increase to Stock Repurchase Program
2. ShangPharma Announces Up to $10 Million Share Repurchase Program
3. Masimo Announces Adoption of Stock Repurchase Program
4. Abaxis Announces Stock Repurchase Program
5. Boston Scientific Announces $1.0B Share Repurchase Program
6. Young Innovations, Inc. Board of Directors Declares Quarterly Dividend and Authorizes Share Repurchase Program
7. Cell Therapeutics, Inc. Announces Institutional Investors Purchase $30 Million of Preferred Stock and Warrants
8. BioSpecifics Technologies Corp. Announces Board Authorization of up to $2 Million Share Repurchase Program
9. China Medical Technologies Announces the Purchase of its ADSs by Chengxuan in the Open Market
10. TPI Board Reinstates Stock Repurchase Program
11. Bacterin International Receives $1 million Initial Investment of $31 Million Purchase Agreement with Lincoln Park Capital Fund, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)...  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent ... 30, 2017.  All comparisons, unless otherwise noted, are to the ... Second Quarter 2017 Highlights include: ... increase of 3.5% Total prescriptions dispensed of ... 7.5% versus 7.6% Gross profit per ...
(Date:8/4/2017)... Aug. 3, 2017  Agragen, LLC, a ... in the biopharmaceutical, nutraceutical, and aquacultural feed sectors, ... its lead drug candidates, AGR131.  This drug is ... from the blood of patients suffering from inflammatory ... bowel disease. ...
(Date:8/2/2017)... BENTON, Ky. , Aug. 2, 2017   Marshall County Hospital in ... (ES) team to proactively reduce the risk of hospital-acquired infections (HAIs). The new addition, ... uses UVC light energy to kill deadly pathogens such as C. diff , MRSA, ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
Breaking Medicine Technology:
(Date:8/24/2017)... ... , ... Indosoft Inc. announces the availability of Q-Suite NG version 1.01. Q-Suite ... experience. It represents a complete redesign of their popular Q-Suite product to meet the ... integration. A full set of APIs allows it to be used as a platform ...
(Date:8/23/2017)... ... 23, 2017 , ... The Arc Mercer, Capitol County’s premier provider of programs ... LGBTQ community organization for people with special needs. The group, the Special Needs Alliance ... state of New Jersey – but the first in the entire country! , SNAP ...
(Date:8/23/2017)... ... August 23, 2017 , ... ... Business Development and Sector Growth. Mr. Smith joins other recent high-profile hires including ... Mr. Smith’s healthcare career began in 1993, helping physician practices and hospitals automate ...
(Date:8/23/2017)... ... August 23, 2017 , ... Based on worldwide research ... efficacy of HBOT in treating and helping to heal addictions and substance abuse ... the similarities of the wounds to the brain from traumatic brain injuries, and ...
(Date:8/23/2017)... ... 23, 2017 , ... Nightingale College continues the semiannual Give Back Day tradition ... Nightingale College dedicates to serving and volunteering for organizations that provide indispensable resources to ... those that need a little extra help. , The College’s Give Back Day ...
Breaking Medicine News(10 mins):